Slocum, Gordon & Co’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
ATO
Slocum, Gordon & Co's ABBV Position: Q2 2026 in Review
Slocum, Gordon & Co reduced its AbbVie (ABBV) stake by 1.4% in Q2 2026, selling an estimated $60.2K and leaving 20,187 shares worth $5.08M. The position accounts for 3.37% of the portfolio, ranked #8.
Slocum, Gordon & Co first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.09M in Q4 2022. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Slocum, Gordon & Co held 20,187 shares of AbbVie worth $5.08M as of Q2 2026.
- Slocum, Gordon & Co sold 280 AbbVie shares in Q2 2026, an estimated $60.2K.
- AbbVie made up 3.37% of Slocum, Gordon & Co's portfolio in Q2 2026, its #8 holding.
- Slocum, Gordon & Co first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
- Slocum, Gordon & Co's AbbVie position peaked at $9.09M in Q4 2022.
- 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Slocum, Gordon & Co's 13F filing for Q2 2026, filed 23 Jul 2026.